Cargando…
Experimental Evaluation of the Hypersensitivity Reactions of a New Glycopeptide Antibiotic Flavancin in Animal Models
Glycopeptide antibiotics are still in demand in clinical practice for treating infections caused by resistant gram-positive pathogens; however, their use is limited due to severe adverse reactions. Their predominant types of side effects are immunoglobulin E-mediated or nonmediated hypersensitivity...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675777/ https://www.ncbi.nlm.nih.gov/pubmed/38004435 http://dx.doi.org/10.3390/ph16111569 |
_version_ | 1785141145604456448 |
---|---|
author | Treshchalin, Michael I. Polozkova, Vasilisa A. Moiseenko, Elena I. Shchekotikhin, Andrey E. Dovzhenko, Svetlana A. Kobrin, Mikhail B. Pereverzeva, Eleonora R. |
author_facet | Treshchalin, Michael I. Polozkova, Vasilisa A. Moiseenko, Elena I. Shchekotikhin, Andrey E. Dovzhenko, Svetlana A. Kobrin, Mikhail B. Pereverzeva, Eleonora R. |
author_sort | Treshchalin, Michael I. |
collection | PubMed |
description | Glycopeptide antibiotics are still in demand in clinical practice for treating infections caused by resistant gram-positive pathogens; however, their use is limited due to severe adverse reactions. Their predominant types of side effects are immunoglobulin E-mediated or nonmediated hypersensitivity reactions. Therefore, the development of new glycopeptide antibiotics with improved toxicity profiles remains an important objective in advancing modern antimicrobial agents. We investigated a new eremomycin aminoalkylamide flavancin, its anaphylactogenic properties, influence on histamine levels in blood plasma, pseudoallergic inflammatory reaction on concanavalin A and the change in the amount of flavancin in the blood plasma after administration. It has been shown that flavancin does not demonstrate anaphylactogenic properties. The injection of flavancin resulted in a level of histamine in the blood three times lower than that caused by vancomycin. The therapeutic dose of vancomycin led to a statistically significant increase in the concanavalin A response index compared to flavancin (54% versus 3.7%). Thus, flavancin does not cause a pseudo-allergic reaction. The rapid decrease in flavancin concentration in the blood and the low levels of histamine in the plasma lead us to assume that any pseudoallergic reactions resulting from flavancin application, if they do occur in clinical practice, will be significantly less compared to the use of vancomycin. |
format | Online Article Text |
id | pubmed-10675777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106757772023-11-07 Experimental Evaluation of the Hypersensitivity Reactions of a New Glycopeptide Antibiotic Flavancin in Animal Models Treshchalin, Michael I. Polozkova, Vasilisa A. Moiseenko, Elena I. Shchekotikhin, Andrey E. Dovzhenko, Svetlana A. Kobrin, Mikhail B. Pereverzeva, Eleonora R. Pharmaceuticals (Basel) Article Glycopeptide antibiotics are still in demand in clinical practice for treating infections caused by resistant gram-positive pathogens; however, their use is limited due to severe adverse reactions. Their predominant types of side effects are immunoglobulin E-mediated or nonmediated hypersensitivity reactions. Therefore, the development of new glycopeptide antibiotics with improved toxicity profiles remains an important objective in advancing modern antimicrobial agents. We investigated a new eremomycin aminoalkylamide flavancin, its anaphylactogenic properties, influence on histamine levels in blood plasma, pseudoallergic inflammatory reaction on concanavalin A and the change in the amount of flavancin in the blood plasma after administration. It has been shown that flavancin does not demonstrate anaphylactogenic properties. The injection of flavancin resulted in a level of histamine in the blood three times lower than that caused by vancomycin. The therapeutic dose of vancomycin led to a statistically significant increase in the concanavalin A response index compared to flavancin (54% versus 3.7%). Thus, flavancin does not cause a pseudo-allergic reaction. The rapid decrease in flavancin concentration in the blood and the low levels of histamine in the plasma lead us to assume that any pseudoallergic reactions resulting from flavancin application, if they do occur in clinical practice, will be significantly less compared to the use of vancomycin. MDPI 2023-11-07 /pmc/articles/PMC10675777/ /pubmed/38004435 http://dx.doi.org/10.3390/ph16111569 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Treshchalin, Michael I. Polozkova, Vasilisa A. Moiseenko, Elena I. Shchekotikhin, Andrey E. Dovzhenko, Svetlana A. Kobrin, Mikhail B. Pereverzeva, Eleonora R. Experimental Evaluation of the Hypersensitivity Reactions of a New Glycopeptide Antibiotic Flavancin in Animal Models |
title | Experimental Evaluation of the Hypersensitivity Reactions of a New Glycopeptide Antibiotic Flavancin in Animal Models |
title_full | Experimental Evaluation of the Hypersensitivity Reactions of a New Glycopeptide Antibiotic Flavancin in Animal Models |
title_fullStr | Experimental Evaluation of the Hypersensitivity Reactions of a New Glycopeptide Antibiotic Flavancin in Animal Models |
title_full_unstemmed | Experimental Evaluation of the Hypersensitivity Reactions of a New Glycopeptide Antibiotic Flavancin in Animal Models |
title_short | Experimental Evaluation of the Hypersensitivity Reactions of a New Glycopeptide Antibiotic Flavancin in Animal Models |
title_sort | experimental evaluation of the hypersensitivity reactions of a new glycopeptide antibiotic flavancin in animal models |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675777/ https://www.ncbi.nlm.nih.gov/pubmed/38004435 http://dx.doi.org/10.3390/ph16111569 |
work_keys_str_mv | AT treshchalinmichaeli experimentalevaluationofthehypersensitivityreactionsofanewglycopeptideantibioticflavancininanimalmodels AT polozkovavasilisaa experimentalevaluationofthehypersensitivityreactionsofanewglycopeptideantibioticflavancininanimalmodels AT moiseenkoelenai experimentalevaluationofthehypersensitivityreactionsofanewglycopeptideantibioticflavancininanimalmodels AT shchekotikhinandreye experimentalevaluationofthehypersensitivityreactionsofanewglycopeptideantibioticflavancininanimalmodels AT dovzhenkosvetlanaa experimentalevaluationofthehypersensitivityreactionsofanewglycopeptideantibioticflavancininanimalmodels AT kobrinmikhailb experimentalevaluationofthehypersensitivityreactionsofanewglycopeptideantibioticflavancininanimalmodels AT pereverzevaeleonorar experimentalevaluationofthehypersensitivityreactionsofanewglycopeptideantibioticflavancininanimalmodels |